Global Fast Melt Tablets Market

Fast Melt Tablets Market Size, Share, Growth Analysis, By Drug Class(Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics), By Indication(CNS Diseases, GI Diseases, CVS Disorders), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2035 | Region: Global | Published Date: July, 2001
Pages: 268 | Tables: 90 | Figures: 76

Fast Melt Tablets Market News

  • In September 2022, ProTab Laboratories, a GMP contract manufacturing facility in Southern California, presents launched its Qk-MeltTechTM technology for the production of quick-melt tablets that dissolve swiftly in the mouth, as quickly as 45 seconds, without the need for water. Customers who have trouble swallowing conventional pills with or without water have a great alternative in ProTab's revolutionary technology. About 35% of the general population experiences dysphagia (difficulty swallowing), which is prevalent across all age groups but is more prevalent in older consumers.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Fast Melt Tablets Market size was valued at USD 14.63 billion in 2019 and is poised to grow from USD 15.65 billion in 2023 to USD 28.65 billion by 2031, growing at a CAGR of 6.95% in the forecast period (2024-2031).

The market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions. 'Pfizer Inc.', 'GlaxoSmithKline plc', 'Teva Pharmaceutical Industries Ltd.', 'Catalent Inc.', 'Novartis AG', 'AstraZeneca plc', 'Bayer AG', 'Janssen Pharmaceuticals, Inc.', 'Eli Lilly and Company', 'Merck & Co., Inc.', 'Roche Holding AG', 'Sanofi S.A.', 'Mylan N.V.', 'Dr. Reddy's Laboratories Ltd.', 'Zydus Cadila', 'Apotex Inc.', 'Cipla Limited', 'Lupin Limited', 'Sun Pharmaceutical Industries Ltd.', 'Torrent Pharmaceuticals Ltd.'

The rise in the older population, who are unable to swallow pills, and the expansion of product promotion meant to raise consumer awareness of patient care. An increase in the demand for cost-effective products and patient compliance to enhance patient quality of life. There is a chance of choking or asphyxia while using oral solid conventional formulations. Additionally, technological advancements in fast melt tablets that dissolve quickly before being swallowed and in less than three minutes have been made to meet pharmacopoeia requirements. This has helped the market's expansion even further.

The expansion of the Fast Melt Tablets market was aided by the growing demand for fast melt tablets from the geriatric population. During the anticipated period, the geriatric population's high adoption of fast-melt tablets will drive demand growth. In a traditional oral formulation, first pass metabolism is a significant problem that can be avoided with the use of a fast melt tablet. The high degree of patient compliance that these drug delivery systems may achieve increases demand. With rapid action, high absorption, and fewer adverse effects for patients, self-administration is feasible. These are the formulations that are encouraging greater acceptance. The creation of this drug delivery system may face some technical difficulties, but these issues can be resolved by conducting in-depth formulation and development research. This improvement will increase the use of this fast-melting pill; which, thereby is likely to create ample market growth opportunities in the upcoming years.

In 2021, North America is expected to have the biggest market share of 42.0%. The regional growth of the market is attributed to the presence of several major players in the market. The market growth in North America can be attributed to the rising geriatric population and frequent US FDA approvals for innovative products. The existence of big firms that provide advanced drug delivery systems and who are funding various R&D operations for the industry are the main elements that make the North American market the largest revenue-generating area in this field. Along with the points already mentioned, other important aspects contributing to market domination include rising disposable income and significant advancements in the healthcare sector. The geriatric population is more inclined to the risk of heart strokes. According to WHO, the incidence and prevalence rate of heart attacks are highest in North America, which is responsible for 0.7 million fatalities each year. Increased prevalence of diseases is likely to create growth opportunities for the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Fast Melt Tablets Market

Report ID: SQSG35I2035

$5,300
BUY NOW GET FREE SAMPLE